# 🧾 What This Document Is This is a **DEFA14A**, a type of SEC filing used for "definitive additional materials." Think of it as an official add-on to a main proxy statement. In this case, it's an **internal FAQ document** for Centessa Pharmaceuticals employees, explaining the company's acquisition

Read summaryView on SEC EDGAR

SEC filings

All filings →

1 recent filing shown in the timeline above. View all SEC filings →

Insider trades

All insider trades →

CNTA has no reported insider trades in the last 90 days.

Institutional holders

All holders →

As of 2025-12-31 · prior 2025-09-30

FARALLON CAPITAL MANAGEMENT LLC$239.5M

9,708,386 sh+124.1%

Avoro Capital Advisors LLC$364.0M

14,555,555 sh+34.7%

GENERAL ATLANTIC, L.P.$153.0M

6,117,715 sh-36.8%

FMR LLC$224.1M

8,961,939 sh+42.8%

EcoR1 Capital, LLC$77.9M

3,115,000 sh+466.4%

BRAIDWELL LP$54.7M

2,188,320 sh● NEW

Deep Track Capital, LP$50.0M

2,000,000 sh● NEW

COMMODORE CAPITAL LP$25.0M

1,000,000 sh-64.9%

People at CNTA

All people →

Accardi Mario Alberto

Quarterly financials

Full financials →

Revenue trend

03/25

$15.0M

NI -$26.1M

06/25

—

NI -$50.3M

09/25

—

NI -$54.9M

RevenueNI = Net Income

EPS trend (diluted)

Latest: $-0.41

Prior: $-0.38

Revenue sparkline